Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
Morse
Michael A
MA
Duke University Medical Center, Department of Medicine, Durham, NC 27710, USA. michael.morse@duke.edu
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D009362:Neoplasm Metastasis; D010793:Phthalazines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D052246:Cyclooxygenase 2 Inhibitors; D010793:Phthalazines; D011725:Pyridines; D042461:Vascular Endothelial Growth Factor A; D003841:Deoxycytidine; D000068258:Bevacizumab; C404768:vatalanib; D000069287:Capecitabine; D066246:ErbB Receptors; D005472:Fluorouracil